Trial
NCT03988114
A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Metastatic Breast Cancer
Intervention
Abemaciclib
Why stopped
Strategic decision due to emerging new data for patients with HR+, HER2- metastatic breast cancer.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-06